Pfizer and Bristol stop a global trial of blood thinner apixaban

11/18/2010 | Bloomberg

Bristol-Myers Squibb and Pfizer have suspended an international, 10,800-participant study of apixaban after deciding that an increase in bleeding caused by the blood thinner outweighs clinical benefits for patients with acute coronary syndrome. "We knew there would be an increase in bleeding," a Bristol-Myers official said. "The question was whether we could achieve enough incremental efficacy to offset the incremental bleeding."

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY